Role of alternative donor allogeneic transplants in the therapy of acute myeloid leukemia

Hany Elmariah, Keith W. Pratz

Research output: Contribution to journalReview articlepeer-review

Abstract

Adult acute myeloid leukemia (AML) is often associated with a poor prognosis, with allogeneic transplantation representing the greatest chance of cure for eligible patients. Historically, the preferred donor source is a human leukocyte antigen-matched blood relative, although only approximately 30% of patients have access to such a donor. Alternative donor sources, including matched unrelated donors, umbilical cord blood, and haploidentical related donors, are available for almost every patient and are increasingly being used for patients without a matched related donor. Survival outcomes with these alternative donor sources now approximate those of matched related donor transplants. Given the safety and success of alternative donor transplants, comparative trials are needed to reassess the optimal donor source for patients with AML. This review summarizes the available data on these alternative donor transplants. Further investigation is needed to contemporize donor selection algorithms, but, in the current era, donor availability should no longer preclude a patient's eligibility for an allogeneic blood or marrow transplant.

Original languageEnglish (US)
Pages (from-to)959-966
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Role of alternative donor allogeneic transplants in the therapy of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this